A preliminary study on effect and safety of anlotinib combined with anti-PD-1 antibody (AK105) in treatment of advanced hepatocellular carcinoma

  Objective  To observe the effect and adverse reactions of anlotinib combined with anti-PD-1 antibody in treatment of advanced hepatocellular carcinoma.

  Methods  Clinical data about 13 patients with advanced hepatocellular carcinoma treated with anlotinib combined with anti-PD-1 antibody from January to August in 2019 in our department were selected, and the curative effect and adverse reactions were observed. The follow-up lasted to September 27th, 2019.

  Results  The main adverse reactions of anlotinib combined with anti-PD-1 antibody in the treatment of advanced hepatocellular carcinoma were hand-foot syndrome, skin reaction and hypertension. No grade 3-4 adverse reactions occurred. In the 13 cases, 3 cases achieved partial remission, and 6 cases achieved stable disease. The objective effective rate was 23.1%, and the disease control rate was 69.2%.

  Conclusion  Anlotinib combined with anti-PD-1 antibody (AK105) shows good curative effect in the treatment of advanced hepatocellular carcinoma with controllable adverse reactions.